                         SEQUENCE LISTING

<110>  ARGENX BVBA
       UNIVERSITY OF BERN
 
<120>  TREATMENT FOR ACUTE MYELOID LEUKAEMIA

<130>  P153963WO00

<150>  GB1709677.7
<151>  2017-06-17

<160>  8     

<170>  PatentIn version 3.5

<210>  1
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Custom antibody fragment

<400>  1

Val Tyr Tyr Met Asn 
1               5   


<210>  2
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Custom antibody fragment

<400>  2

Asp Ile Asn Asn Glu Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val Lys 
1               5                   10                  15      


Gly 
    


<210>  3
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Custom antibody fragment

<400>  3

Asp Ala Gly Tyr Ser Asn His Val Pro Ile Phe Asp Ser 
1               5                   10              


<210>  4
<211>  122
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Custom antibody fragment

<400>  4

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Val Tyr 
            20                  25                  30          


Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Asp Ile Asn Asn Glu Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Ala Gly Tyr Ser Asn His Val Pro Ile Phe Asp Ser Trp 
            100                 105                 110         


Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120         


<210>  5
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Custom antibody fragment

<400>  5

Gly Leu Lys Ser Gly Ser Val Thr Ser Asp Asn Phe Pro Thr 
1               5                   10                  


<210>  6
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Custom antibody fragment

<400>  6

Asn Thr Asn Thr Arg His Ser 
1               5           


<210>  7
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Custom antibody fragment

<400>  7

Ala Leu Phe Ile Ser Asn Pro Ser Val Glu 
1               5                   10  


<210>  8
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Custom antibody fragment

<400>  8

Gln Ala Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly 
1               5                   10                  15      


Thr Val Thr Leu Thr Cys Gly Leu Lys Ser Gly Ser Val Thr Ser Asp 
            20                  25                  30          


Asn Phe Pro Thr Trp Tyr Gln Gln Thr Pro Gly Gln Ala Pro Arg Leu 
        35                  40                  45              


Leu Ile Tyr Asn Thr Asn Thr Arg His Ser Gly Val Pro Asp Arg Phe 
    50                  55                  60                  


Ser Gly Ser Ile Leu Gly Asn Lys Ala Ala Leu Thr Ile Thr Gly Ala 
65                  70                  75                  80  


Gln Ala Asp Asp Glu Ala Glu Tyr Phe Cys Ala Leu Phe Ile Ser Asn 
                85                  90                  95      


Pro Ser Val Glu Phe Gly Gly Gly Thr Gln Leu Thr Val Leu Gly 
            100                 105                 110     


